Clinical Trial

Aveir Leadless Pacemaker Japan PMS

Recruiting
View on ClinicalTrials.gov →
Summary
The primary purpose of the PMS is to collect safety information on the Aveir DR leadless cardiac pacemaker (LP) system in a population indicated for de novo dual-chamber pacing. Additionally, the PMS will collect data on rollover patients from the Aveir DR i2i IDE, Aveir AR LP in patients indicated for single-chamber pacing in the right atrium, and upgradeability in patients implanted with single-chamber Aveir atrial or ventricular LP that require an upgrade to a dual-chamber Aveir LP.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-30; most recent amendment 2026-05-11.
Trial Details
NCT Number NCT07106788
Lead Sponsor Abbott Medical Devices
Conditions Leadless Pacemaker
Enrollment 304 participants
Start Date 2025-05-26
Primary Completion 2029-11 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-13